Jason L Schwartz, PhD

• A David Paltiel
• Daniel Boffa
• Jeph Herrin
• Joseph Ross
• Linda Niccolai
• Maureen Canavan
• Michael S. Leapman
• Michelle Salazar
• Saad B. Omer

Health Policy; History of Medicine; Public Health; Risk; Sociology, Medical; Vaccination; Evidence-Based Medicine

Bioethics; Health Policy; History of Medicine and Science; Infectious Diseases; Vaccines; Pharmaceuticals and Medical Devices; Regulatory Affairs; COVID-19

• Publicationslist and links available at http://jschwartz.yale.edu/publications/index.aspx
• Lessons from the failure of human papillomavirus vaccine state requirements.Schwartz JL, Caplan AL, Faden RR, Sugarman J. Lessons from the failure of human papillomavirus vaccine state requirements. Clinical Pharmacology And Therapeutics 2007, 82:760-3.
• HPV vaccination's second act: promotion, competition, and compulsion.Schwartz JL. HPV vaccination's second act: promotion, competition, and compulsion. American Journal Of Public Health 2010, 100:1841-4.
• Vaccination refusal: ethics, individual rights, and the common good.Schwartz JL, Caplan AL. Vaccination refusal: ethics, individual rights, and the common good. Primary Care 2011, 38:717-28, ix.
• Ethics of vaccination programs.Schwartz JL, Caplan AL. Ethics of vaccination programs. Current Opinion In Virology 2011, 1:263-7.
• The first rotavirus vaccine and the politics of acceptable risk.Schwartz JL. The first rotavirus vaccine and the politics of acceptable risk. The Milbank Quarterly 2012, 90:278-310.
• New media, old messages: themes in the history of vaccine hesitancy and refusal.Schwartz JL. New media, old messages: themes in the history of vaccine hesitancy and refusal. The Virtual Mentor : VM 2012, 14:50-5.
• Immune to addiction: the ethical dimensions of vaccines against substance abuse.Young MJ, Sisti DA, Rimon-Greenspan H, Schwartz JL, Caplan AL. Immune to addiction: the ethical dimensions of vaccines against substance abuse. Nature Immunology 2012, 13:521-4.
• Evidence and ethics in mandatory vaccination policies.Schwartz JL. Evidence and ethics in mandatory vaccination policies. The American Journal Of Bioethics : AJOB 2013, 13:46-8.
• "Model" patients and the consequences of provider responses to vaccine hesitancy.Schwartz JL. "Model" patients and the consequences of provider responses to vaccine hesitancy. Human Vaccines & Immunotherapeutics 2013, 9:2663-5.
• Rotavirus vaccines, intussusception, and risk-benefit assessments.Schwartz JL. Rotavirus vaccines, intussusception, and risk-benefit assessments. JAMA Pediatrics 2013, 167:1093-4.
• A half-century of prevention--the Advisory Committee on Immunization Practices.Schwartz JL, Mahmoud A. A half-century of prevention--the Advisory Committee on Immunization Practices. The New England Journal Of Medicine 2014, 371:1953-6.
• State Vaccination Requirements for HPV and Other Vaccines for Adolescents, 1990-2015.Schwartz JL, Easterling LA. State Vaccination Requirements for HPV and Other Vaccines for Adolescents, 1990-2015. JAMA 2015, 314:185-6.
• Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study.Schwartz JL. Fifty Years of Expert Advice - Pharmaceutical Regulation and the Legacy of the Drug Efficacy Study. The New England Journal Of Medicine 2016, 375:2015-2017.
• The Missions of National Commissions: Mapping the Forms and Functions of Bioethics Advisory Bodies.Schmidt H, Schwartz JL. The Missions of National Commissions: Mapping the Forms and Functions of Bioethics Advisory Bodies. Kennedy Institute Of Ethics Journal 2016, 26:431-456.
• When Not All That Counts Can Be Counted: Economic Evaluations And The Value Of Vaccination.Schwartz JL, Mahmoud A. When Not All That Counts Can Be Counted: Economic Evaluations And The Value Of Vaccination. Health Affairs (Project Hope) 2016, 35:208-11.
• Vaccine Pricing and US Immunization Policies.Schwartz JL. Vaccine Pricing and US Immunization Policies. JAMA 2016, 316:226.
• State-Level Voting Patterns and Adolescent Vaccination Coverage in the United States, 2014.Bernstein S, North A, Schwartz J, Niccolai LM. State-Level Voting Patterns and Adolescent Vaccination Coverage in the United States, 2014. American Journal Of Public Health 2016, 106:1879-81.
• The Uncertain Future of Human Papillomavirus Vaccination School Requirements.Schwartz JL. The Uncertain Future of Human Papillomavirus Vaccination School Requirements. Pediatrics 2016, 138.
• Real-World Evidence, Public Participation, and the FDA.Schwartz JL. Real-World Evidence, Public Participation, and the FDA. The Hastings Center Report 2017, 47:7-8.
• Vaccines and the Trump Administration-Reasons for Optimism Amid Uncertainty.Schwartz JL. Vaccines and the Trump Administration-Reasons for Optimism Amid Uncertainty. American Journal Of Public Health 2017, 107:1892-1893.
• Using campaigns to improve perceptions of the value of adult vaccination in the United States: Health communication considerations and insights.Nowak GJ, Shen AK, Schwartz JL. Using campaigns to improve perceptions of the value of adult vaccination in the United States: Health communication considerations and insights. Vaccine 2017, 35:5543-5550.
• Achieving an Optimal Childhood Vaccine Policy.Opel DJ, Schwartz JL, Omer SB, Silverman R, Duchin J, Kodish E, Diekema DS, Marcuse EK, Orenstein W. Achieving an Optimal Childhood Vaccine Policy. JAMA Pediatrics 2017, 171:893-896.
• A Broader Bioethics: Topic Selection and the Impact of National Bioethics Commissions.Schwartz JL. A Broader Bioethics: Topic Selection and the Impact of National Bioethics Commissions. The Hastings Center Report 2017, 47 Suppl 1:S17-S19.
• Costs, Consequences, and Policy Responses of Vaccine-Preventable Disease Outbreaks.Schwartz JL. Costs, Consequences, and Policy Responses of Vaccine-Preventable Disease Outbreaks. JAMA Pediatrics 2018, 172:805-807.
• The Spanish Flu, Epidemics, and the Turn to Biomedical Responses.Schwartz JL. The Spanish Flu, Epidemics, and the Turn to Biomedical Responses. American Journal Of Public Health 2018, 108:1455-1458.
• Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.Zhang AD, Schwartz JL, Ross JS. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015. The Milbank Quarterly 2019, 97:796-819.
• The Vaccines for Children Program at 25 - Access, Affordability, and Sustainability.Schwartz JL, Colgrove J. The Vaccines for Children Program at 25 - Access, Affordability, and Sustainability. The New England Journal Of Medicine 2020, 382:2277-2279.
• Meningococcal Serogroup B Vaccine Policies and Recommendations at U.S. Colleges and Universities.Schwartz JL, Lawrence JC. Meningococcal Serogroup B Vaccine Policies and Recommendations at U.S. Colleges and Universities. American Journal Of Preventive Medicine 2020, 59:618-619.
• Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust.Schwartz JL. Evaluating and Deploying Covid-19 Vaccines - The Importance of Transparency, Scientific Integrity, and Public Trust. The New England Journal Of Medicine 2020, 383:1703-1705.
• Evaluation of Cancer Care After Medicaid Expansion Under the Affordable Care Act.Salazar MC, Canavan ME, Walters SL, Herrin J, Schwartz JL, Leapman M, Boffa DJ. Evaluation of Cancer Care After Medicaid Expansion Under the Affordable Care Act. JAMA Network Open 2020, 3:e2017544.
• Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration.Puthumana J, Egilman AC, Zhang AD, Schwartz JL, Ross JS. Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration. JAMA Internal Medicine 2021, 181:559-560.
• Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy.Paltiel AD, Schwartz JL, Zheng A, Walensky RP. Clinical Outcomes Of A COVID-19 Vaccine: Implementation Over Efficacy. Health Affairs (Project Hope) 2021, 40:42-52.
• Equitable global access to coronavirus disease 2019 vaccines.Schwartz JL. Equitable global access to coronavirus disease 2019 vaccines. BMJ (Clinical Research Ed.) 2020, 371:m4735.
• Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.Paltiel AD, Zheng A, Schwartz JL. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment. Annals Of Internal Medicine 2021, 174:568-570.
• Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020.Zhang AD, Puthumana J, Egilman AC, Schwartz JL, Ross JS. Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020. Journal Of General Internal Medicine 2021.